Canet Mark J, Hardwick Rhiannon N, Lake April D, Dzierlenga Anika L, Clarke John D, Goedken Michael J, Cherrington Nathan J
University of Arizona, Department of Pharmacology and Toxicology, Tucson, Arizona (M.J.C., R.N.H., A.D.L., A.L.D., J.D.C., N.J.C.); and Rutgers University, Office of Translational Science, New Brunswick, New Jersey (M.J.G.).
University of Arizona, Department of Pharmacology and Toxicology, Tucson, Arizona (M.J.C., R.N.H., A.D.L., A.L.D., J.D.C., N.J.C.); and Rutgers University, Office of Translational Science, New Brunswick, New Jersey (M.J.G.)
Drug Metab Dispos. 2015 Feb;43(2):266-72. doi: 10.1124/dmd.114.060574. Epub 2014 Dec 8.
Nonalcoholic fatty liver disease is the most common chronic liver disease, which can progress to nonalcoholic steatohepatitis (NASH). Previous investigations demonstrated alterations in the expression and activity of hepatic drug transporters in NASH. Moreover, studies using rodent models of cholestasis suggest that compensatory changes in kidney transporter expression occur to facilitate renal excretion during states of hepatic stress; however, little information is currently known regarding extrahepatic regulation of drug transporters in NASH. The purpose of the current study was to investigate the possibility of renal drug transporter regulation in NASH across multiple experimental rodent models. Both rat and mouse NASH models were used in this investigation and include: the methionine and choline-deficient (MCD) diet, atherogenic diet, fa/fa rat, ob/ob and db/db mice. Histologic and pathologic evaluations confirmed that the MCD and atherogenic rats as well as the ob/ob and db/db mice all developed NASH. In contrast, the fa/fa rats did not develop NASH but did develop extensive renal injury compared with the other models. Renal mRNA and protein analyses of xenobiotic transporters suggest that compensatory changes occur in NASH to favor increased xenobiotic secretion. Specifically, both apical efflux and basolateral uptake transporters are induced, whereas apical uptake transporter expression is repressed. These results suggest that NASH may alter the expression and potentially function of renal drug transporters, thereby impacting drug elimination mechanisms in the kidney.
非酒精性脂肪性肝病是最常见的慢性肝病,可进展为非酒精性脂肪性肝炎(NASH)。先前的研究表明,NASH中肝脏药物转运体的表达和活性发生了改变。此外,使用胆汁淤积啮齿动物模型的研究表明,在肝脏应激状态下,肾脏转运体表达会发生代偿性变化,以促进肾脏排泄;然而,目前关于NASH中外周药物转运体调节的信息知之甚少。本研究的目的是通过多个实验性啮齿动物模型研究NASH中肾脏药物转运体调节的可能性。本研究使用了大鼠和小鼠NASH模型,包括:蛋氨酸和胆碱缺乏(MCD)饮食、致动脉粥样硬化饮食、fa/fa大鼠、ob/ob和db/db小鼠。组织学和病理学评估证实,MCD和致动脉粥样硬化大鼠以及ob/ob和db/db小鼠均发展为NASH。相比之下,fa/fa大鼠未发展为NASH,但与其他模型相比,确实出现了广泛的肾损伤。对外源性物质转运体的肾脏mRNA和蛋白质分析表明,NASH中发生了代偿性变化,有利于增加外源性物质的分泌。具体而言,顶端外排和基底外侧摄取转运体均被诱导,而顶端摄取转运体的表达受到抑制。这些结果表明,NASH可能会改变肾脏药物转运体的表达及其潜在功能,从而影响肾脏中的药物消除机制。